These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24824309)

  • 1. Molecular pathways: targeting death receptors and smac mimetics.
    Fulda S
    Clin Cancer Res; 2014 Aug; 20(15):3915-20. PubMed ID: 24824309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smac mimetics as IAP antagonists.
    Fulda S
    Semin Cell Dev Biol; 2015 Mar; 39():132-8. PubMed ID: 25550219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalent SMAC Mimetics for Treating Cancer by Antagonizing Inhibitor of Apoptosis Proteins.
    Zhu H; Li Y; Liu Y; Han B
    ChemMedChem; 2019 Dec; 14(23):1951-1962. PubMed ID: 31692274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IAP Proteins Antagonist: An Introduction and Chemistry of Smac Mimetics under Clinical Development.
    Ali R; Singh S; Haq W
    Curr Med Chem; 2018; 25(31):3768-3795. PubMed ID: 29532750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promises and Challenges of Smac Mimetics as Cancer Therapeutics.
    Fulda S
    Clin Cancer Res; 2015 Nov; 21(22):5030-6. PubMed ID: 26567362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of small-molecule Smac mimetics as IAP antagonists.
    Wang S
    Curr Top Microbiol Immunol; 2011; 348():89-113. PubMed ID: 21072626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smac Mimetics to Therapeutically Target IAP Proteins in Cancer.
    Fulda S
    Int Rev Cell Mol Biol; 2017; 330():157-169. PubMed ID: 28215531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smac mimetics as new cancer therapeutics.
    Chen DJ; Huerta S
    Anticancer Drugs; 2009 Sep; 20(8):646-58. PubMed ID: 19550293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of smac mimetics; chemotype differentiation based on physical association with caspase regulators and cellular transport.
    Talbott RL; Borzilleri RM; Chaudhry C; Fargnoli J; Shen H; Fairchild C; Barnhart B; Ortega M; McDonagh TE; Vuppugalla R; Vite GD; Hunt JT; Gottardis M; Naglich JG
    Exp Cell Res; 2015 Nov; 338(2):251-60. PubMed ID: 26302264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of small-molecule peptidic and nonpeptidic Smac mimetics.
    Sun H; Nikolovska-Coleska Z; Yang CY; Qian D; Lu J; Qiu S; Bai L; Peng Y; Cai Q; Wang S
    Acc Chem Res; 2008 Oct; 41(10):1264-77. PubMed ID: 18937395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways: targeting inhibitor of apoptosis proteins in cancer--from molecular mechanism to therapeutic application.
    Fulda S
    Clin Cancer Res; 2014 Jan; 20(2):289-95. PubMed ID: 24270683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule inhibitor of apoptosis proteins antagonists: a patent review.
    Hird AW; Aquila BM; Hennessy EJ; Vasbinder MM; Yang B
    Expert Opin Ther Pat; 2015 Jul; 25(7):755-74. PubMed ID: 25980951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy.
    de Almagro MC; Vucic D
    Exp Oncol; 2012 Oct; 34(3):200-11. PubMed ID: 23070005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.
    Zobel K; Wang L; Varfolomeev E; Franklin MC; Elliott LO; Wallweber HJ; Okawa DC; Flygare JA; Vucic D; Fairbrother WJ; Deshayes K
    ACS Chem Biol; 2006 Sep; 1(8):525-33. PubMed ID: 17168540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
    Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F
    FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting inhibitor of apoptosis proteins for therapeutic intervention.
    Ndubaku C; Cohen F; Varfolomeev E; Vucic D
    Future Med Chem; 2009 Nov; 1(8):1509-25. PubMed ID: 21426063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homo- and heterodimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part I: Synthesis.
    Manzoni L; Belvisi L; Bianchi A; Conti A; Drago C; de Matteo M; Ferrante L; Mastrangelo E; Perego P; Potenza D; Scolastico C; Servida F; Timpano G; Vasile F; Rizzo V; Seneci P
    Bioorg Med Chem; 2012 Nov; 20(22):6687-708. PubMed ID: 23036335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMAC Mimetics for the Treatment of Lung Carcinoma: Present Development and Future Prospects.
    Pandey R; Bisht P; Wal P; Murti K; Ravichandiran V; Kumar N
    Mini Rev Med Chem; 2024; 24(14):1334-1352. PubMed ID: 38275029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule pan-IAP antagonists: a patent review.
    Flygare JA; Fairbrother WJ
    Expert Opin Ther Pat; 2010 Feb; 20(2):251-67. PubMed ID: 20100005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.